Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 15/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29780245 | 1.00 | ATR (0.40) | ATRCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL27228058 | 0.83 | CYP4F2 (0.44) | ATRCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL30860948 | 0.83 | CYP4F2 (0.44) | ATRCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL20324247 | 0.81 | CYP4F2 (0.44) | ATRCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL31602907 | 0.80 | CYP4F2 (0.37) | ATRCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL27227802 | 0.80 | ATR (0.41) | ATRCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL23478362 | 0.80 | CYP4F2 (0.37) | ATRCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL30860931 | 0.80 | ATR (0.41) | ATRCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL25324455 | 0.73 | RET (0.42) | ATRCYP4F2CYP4A11RXRARXRB | |
| SCHEMBL767841 | 0.73 | RXRA (0.43) | ATRCYP4F2CYP4A11RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024438-A1 | INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4069212-A1 | INHIBITORS OF HIF-2ALPHA | Arcus Biosciences, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-114760994-A | Inhibitors of HIF-2 alpha | 艾库斯生物科学有限公司 | 2022-07-15 | — | — | CN | disclosed |
| WO-2021113436-A1 | INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113436-A1 | INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024438-A1 | INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | ATR 2506/4885CYP4F2 2033/4885CYP4A11 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.